Gothenburg, Sweden

Magnus Polla


Average Co-Inventor Count = 1.9

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Göteborg, SE (2001)
  • Gothenburg, SE (2005 - 2008)
  • Mölndal, SE (2008 - 2012)

Company Filing History:


Years Active: 2001-2012

Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Magnus Polla

Introduction

Magnus Polla is a notable inventor based in Gothenburg, Sweden. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing novel compounds that have therapeutic applications, particularly in the area of protease inhibition.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Compounds 148." This invention relates to novel pharmaceutically useful compounds that serve as competitive inhibitors of trypsin-like serine proteases, especially thrombin. The patent outlines their use as medicaments, pharmaceutical compositions containing them, and synthetic routes for their production. Another significant patent is for "2,5-disubstituted 3-mercaptopentanoic acid." This invention concerns compounds that inhibit carboxypeptidase U, which can be beneficial in the prevention and treatment of various diseases. The patent also discusses processes for preparing these new compounds and their use in pharmaceutical compositions.

Career Highlights

Magnus Polla is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to the development of innovative therapies that address critical health challenges.

Collaborations

Throughout his career, Magnus has collaborated with esteemed colleagues, including Marcel Linschoten and Christer Alstermark. These collaborations have further enhanced the impact of his inventions in the pharmaceutical industry.

Conclusion

Magnus Polla's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new therapeutic options that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…